Table 3.
Effects of Drug Interventions on Lipid Profile and Insulin Sensitivity for Lipolysisa
| Dutasteride (n = 16) |
Finasteride (n = 16) |
Tamsulosin (n = 14) |
P, ANOVA | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Before | After | Change | Before | After | Change | Before | After | Change | ||
| Total cholesterol, mM | 4.4 (0.2) | 4.3 (0.2) | −0.1 (0.1) | 4.9 (0.3) | 5.0 (0.3) | +0.1 (0.1) | 5.2 (0.3) | 4.9 (0.3) | −0.3 (0.1) | .08 |
| HDL-cholesterol, mM | 1.3 (0.1) | 1.3 (0.1) | −0.0 (0.0) | 1.3 (0.1) | 1.3 (0.1) | 0.0 (0.0) | 1.4 (0.2) | 1.3 (0.1) | −0.1 (0.1) | .47 |
| LDL-cholesterol, mM | 2.6 (0.2) | 2.6 (0.2) | +0.0 (0.1) | 3.0 (0.3) | 3.1 (0.3) | +0.1 (0.1) | 3.2 (0.2) | 3.1 (0.3) | −0.1 (0.2) | .43 |
| Triglycerides, mM | 1.3 (0.1) | 1.1 (0.2) | −0.2 (0.1) | 1.2 (0.2) | 1.2 (0.2) | +0.0 (0.1) | 1.4 (0.2) | 1.2 (0.2) | −0.1 (0.1) | .38 |
| Fasting before infusion | ||||||||||
| Glycerol, μM | 48.4 (5.3) | 67.9 (18.4) | 19.5 (14.5) | 50.4 (7.2) | 47.7 (7.0) | −2.7 (7.3) | 53.6 (9.5) | 42.3 (5.4) | −11.3 (5.8) | .10 |
| NEFAs, μM | 485.1 (53.2) | 523.8 (69.7) | 38.7 (73.7) | 443.9 (54.8) | 493.1 (43.8) | 49.2 (51.2) | 649.4 (71.4) | 580.2 (102.3) | −69.2 (61.6) | .37 |
| During tracer infusion without insulin infusion | ||||||||||
| Glycerol, μM | 41.2 (5.0) | 45.7 (6.3) | +4.5 (5.2) | 42.8 (4.7) | 38.4 (4.7) | −4.4 (4.2) | 42.3 (6.3) | 38.2 (4.3) | −4.0 (3.7) | .28 |
| Ra glycerol, μmol/kg FFM/min | 2.54 (0.34) | 2.78 (0.42) | 0.24 (0.21) | 2.32 (0.28) | 2.27 (0.16) | −0.04 (0.25) | 3.14 (0.39) | 3.04 (0.39) | −0.09 (0.30) | .60 |
| NEFAs, μM | 484.2 (52.5) | 520.1 (51.7) | 35.9 (49.8) | 479.6 (58.4) | 497.5 (63.3) | 17.9 (51.5) | 628.9 (59.8) | 577.2 (53.3) | −51.7 (51.2) | .46 |
| During low-dose insulin infusion | ||||||||||
| Glycerol, μM | 18.0 (2.6) | 22.4 (4.0) | 4.4 (2.6) | 17.4 (3.1) | 16.0 (3.0) | −1.5 (3.1) | 22.6 (6.7) | 16.0 (2.6) | −6.7 (6.1) | .17 |
| Ra glycerol, μmol/kg FFM/min | 1.23 (0.15) | 1.39 (0.17) | 0.16 (0.15) | 1.32 (0.18) | 1.30 (0.17) | −0.02 (0.10) | 1.99 (0.36) | 1.60 (0.12) | −0.39 (0.32) | .16 |
| NEFAs, μM | 184.9 (27.9) | 245.2 (36.6) | 60.3 (30.0)b | 193.4 (32.9) | 189.7 (33.6) | −3.7 (14.9) | 295.1 (56.2) | 214.1 (22.1) | −81.0 (60.4) | .04 |
| During high-dose insulin infusion | ||||||||||
| Glycerol, μM | 14.7 (2.67) | 13.1 (2.87) | −1.8 (1.3) | 10.6 (2.39) | 8.9 (2.14) | −1.7 (2.0) | 15.0 (5.56) | 6.9 (1.98) | −8.1 (4.5) | .21 |
| NEFAs, μM | 36.3 (4.0) | 39.0 (5.9) | 2.3 (5.9) | 37.1 (4.5) | 37.8 (4.9) | 0.7 (3.7) | 53.3 (9.8) | 32.2 (2.8) | −21.1 (9.8) | .12 |
Abbreviations: FFM, fat-free mass; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
a
Data are mean (SEM) of the values from each study day obtained at baseline after overnight fast and as an average of 4 measurements in 15-minute steady-state periods after low-dose or high-dose insulin infusions (n = 11–12 per group). Steady state was confirmed, with the relative SD of the tracer to tracee ratios of d5-glycerol to glycerol between 1.2% and 11.7%. ANOVA was conducted on absolute change in each variable from baseline, with LSD post hoc testing if ANOVA was significant (P < .05).
b
P ≤ .01 vs tamsulosin.